1 of 1
Story summary
- Grail, Inc.'s Galleri blood test for early cancer detection failed to achieve its primary goal in a large study with England's National Health Service.
- The Galleri test is not approved by the U.S. Food and Drug Administration (FDA) and is available for $1,000.
- In 2025, Grail sold 185,000 tests, generating $136.8 million in revenue.
- Following the study results, Grail's shares fell 47% in after-hours trading.
